Navigation Links
Janssen Diagnostics Expands Research Portfolio to Include Next-Generation Sequencing
Date:8/25/2014

RARITAN, N.J., Aug. 25, 2014 /PRNewswire/ -- Janssen Diagnostics, LLC today announced the addition of next-generation sequencing (NGS) to the portfolio of services it provides pharmaceutical and academic researchers. With this announcement, Janssen Diagnostics continues to drive innovative solutions for its lab services customers by expanding its lab services offering in rare cell detection beyond its core competencies: the gold-standard CELLSEARCH® System, proteomics, and fluorescent in situ hybridization.

Janssen Diagnostics has entered into an agreement with Asuragen Inc. enabling them to offer NGS to their customers on Asuragen's proprietary SuraSeq™ panels. This NGS platform allows the rapid analysis of DNA and has proven applicability in oncology research. When used in tandem with the CELLSEARCH® System, this technology can provide researchers with a more comprehensive understanding of tumor biology, drug response, and drug resistance through the capture and interrogation of rare cells (circulating tumor cells, circulating multiple myeloma cells, and others captured via the CELLSEARCH® System).

"We are very pleased to offer NGS services to our research customers," commented Kristen Hollingsworth, Global Business Leader, Janssen Diagnostics, LLC. "Our lab services team is focused on giving researchers tools to identify biomarkers that may be clinically relevant, and track their subjects' status over the course of their clinical trials – we call it 'dynamic monitoring'."

Performing NGS on rare cells can help detect hidden biological processes. As an example, NGS on circulating tumor cells (CTCs) provides additional insights for cancer researchers as studies have demonstrated heterogeneity in information obtained from a primary tumor versus that which is measured in detectable CTCs.

About Janssen Diagnostics

At Janssen Diagnostics we are passionate about the promise of personalized medicine and its potential to improve outcomes for specific patients through targeted therapies.

We aspire to help doctors and researchers better identify, prevent or intervene earlier with diseases, or cure people with the right medicines for the right person, at the right time.

Being part of Janssen puts us in a strong position, enabling us to bridge Janssen's extensive pharmaceutical knowledge-base and global capabilities, with our own heritage and talent in research technology, diagnostics and health information technology to deliver integrated solutions into the hands of healthcare providers.

The best way to further our aspirations in the personalized medicine space is to move away from the traditional business model and adopt a more open model that is based on developing the best technologies, either in-house or by partnering with those who own them, to ultimately improve patient outcomes in collaboration with our customers.

What makes Janssen Diagnostics unique is the concentration of minds, personnel and skills at the heart of Pharma R&D, specifically organized to develop and commercialize products and services around meeting patient needs of both today and tomorrow.

Media Contacts:

Frederik Wittock
Janssen Global Services, LLC
fwittock@its.jnj.com or +32 14 60 57 24

Scott Canady
scanady2@its.jnj.com or 809-481-2781


'/>"/>
SOURCE Janssen Diagnostics, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Contraceptives Market 2014-2018: Key Vendors are Actavis, Bayer, Johnson & Johnsons, Janssen, Merck & Co, Pfizer and Teva
2. Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.
3. Global Transdermal Drug Delivery Market 2014-2018: Key Vendors are ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen and Novartis
4. Janssen Launches Online Healthy Minds Video Series
5. Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
6. Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
7. Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gileads Sofosbuvir and Janssen/Medivirs Simeprevir
8. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
9. Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention
10. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
11. Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017  Andre, DiMino, CEO of ... and manufacturer of innovative technologies and products, commented on ... on February 21, 2017 in the Company,s quarterly report ... ADMT CEO Andre, DiMino stated "During the quarter ... plan by devoting a larger portion of our engineering ...
(Date:2/22/2017)... 2017 Summary Provides understanding ... and agreements entered into by the worlds leading ... http://www.reportlinker.com/p03605670-summary/view-report.html Description The Global Myocardial Infarction ... to partnering deals and agreements entered into by ... Trends in partnering deals - Top deals ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... heart failure partnering deals and agreements entered into ... the full report: http://www.reportlinker.com/p03605673-summary/view-report.html Description ... report provides understanding and access to partnering deals ... healthcare companies. - Trends in partnering ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... VitreosHealth ... each Medicare Advantage member’s risk, identify any gaps-in-coding, as well as gaps-in-care ... transform the HCC Risk Adjustment process from a typical fragmented process to ...
(Date:2/22/2017)... Fla. (PRWEB) , ... February 22, 2017 , ... ... is just as effective on smaller and sometimes harder to reach ones, according ... were presented at the International Stroke Conference in Houston by Ricardo A. Hanel, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the ... national TV host Tom Seay and his production crew. Tom Seay’s program “Best ... around the world. Saddle Sidekicks will be featured on April 6, 2017. After ...
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of the internet, IdrisArkette.com ... checklist. Over a period of just 24 months, thousands of individuals interested in a ... called T.A.D. , “The internet is not getting quieter. In fact it’s becoming noisier ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management ... on the App Store and Google Play . Florida-based Sober Network, ... and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app ...
Breaking Medicine News(10 mins):